ANRS0002S CoviCompare-P
A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS-CoV-2 infection administered with two doses of vaccine (D1-D29) and in adult volunteers with documented history of SARS-CoV-2 infection (of more than 5 months) administered with only one dose of vaccine.
Last updated on 27 February 2024
Main objective
To assess the humoral immune response to the COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with or without documented history of SARS CoV-2 infection, 28 days after the first or second injection respectively.
Thématique
COVID-19
Status
In progress
Population
Adults
You wish to access biological samples from this study
Samples from the ANRS Emerging Infectious Diseases Biobank are made available after obtaining the opinion of the Scientific Advisory Board of the study concerned if it is ongoing, or after obtaining the opinion of the Director of the ANRS Emerging Infectious Diseases Biobank if the study has been completed.
For all requests for use, please complete the form below and send it to biobanque@anrs.fr
You are participating or have participated in this study
On the form above, you will find information on the ancillary/ancillary studies for which your data/samples will be or may have been re-used if you gave your consent at the time of inclusion.
If you would like to find out more about your participation in a clinical study, please see the section below.
Consult the participants’ area